BRAIN and NERVE－神経研究の進歩66巻10号

2014年10月発行

特集 分子を撃つ　神経疾患治療の新しい水平線

IL-6受容体：トシリズマブ—視神経脊髄炎への応用

著者： 山村隆¹ 荒木学²

所属機関： ¹国立精神・神経医療研究センター神経研究所免疫研究部 ²国立精神・神経医療研究センター病院多発性硬化症センター

ページ範囲：P.1159 - P.1165

文献概要

視神経脊髄炎では，プラズマブラストによるIL-6依存性の抗アクアポリン4抗体産生が病態に関与することに着目し，筆者らはヒト化抗IL-6受容体抗体トシリズマブによる治療の可能性を検証した。8症例に対する1年間の投与の結果では，年間再発回数，神経原性疼痛および疲労感の軽減が確認され，視神経脊髄炎におけるIL-6阻害療法は有望と考えられた。

参考文献

1) Araki M, Matuoka T, Miyamoto K, Kusunoki S, Okamoto T, et al: Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology 82: 1302-1306, 2014

2) Chihara N, Aranami T, Sato W, Miyazaki Y, Miyake S, et al: Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A 108: 3701-3706, 2011

3) Chihara N, Aranami T, Oki S, Matsuoka T, Nakamura M, et al: Plasmablasts as migratory IgG-producing cells in the pathogeneis of neuromyelitis optica. PLOS ONE 8: e83036, 2013

4) Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, et al: A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364: 2106-2112, 2004

5) Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG: The spectrum of neuromyelitis optica. Lancet Neurol 6: 805-815, 2007

6) Jarius S, Wildemann B: AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol 6: 383-392, 2010

7) Saadoun S, Waters P, Bell A, Vincent A, Verkman AS, et al: Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 133: 349-361, 2010

8) Bradl M, Misu T, Takahashi T, Watanabe M, Mader S, et al: Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol 66: 630-643, 2009

9) Bennett JL, Lam C, Kalluri SR, Saikali P, Bautista K, et al: Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol 66: 617-629, 2009

10) Takano R, Misu T, Takahashi T, Sato S, Fujihara K, et al: Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study. Neurology 75: 208-216, 2010

11) Fujihara K, Misu T, Nakashima I, Takahashi T, Bradl M, et al: Neuromyelitis optica should be classified as an astrocytopathy rather than a demyelinating disease. Clin Exp Neuroimmunol 3: 58-73, 2012

12) Uzawa A, Mori M, Arai K, Sato Y, Hayakawa S, et al: Cytokine and chemokine profiles in neuromyelitis optica: significance of inyterleukin-6．Mult Scler 16: 1443-1452, 2010

13) Okada K, Matsushita T, Kira J, Tsuji S: B-cell activating factor of the TNF family is upregulated in neuromyelitis optica. Neurology 74: 177-178, 2010

14) Araki M, Aranami T, Matsuoka T, Nakamura M, Miyake S, et al: Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab. Mod Rheumatol 23: 827, 2013

15) Tanaka T, Narazaki M, Kishimoto T: Therapeutic targeting of the interleukin-6 receptor. Annu Rev Pharmacol Toxicol 52: 199-219, 2012

16) Warabi Y, Matsumoto Y, Hayashi H: Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination. J Neurol Sci 252: 57-61, 2007

17) Shimizu J, Hatanaka Y, Hasegawa M, Iwata A, Sugimoto I, et al: IFNb-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. Neurology 75: 1423-1427, 2010

18) Min JH, Kim BJ, Lee KH: Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler 18: 113-115, 2012

19) Kleiter I, Hellwig K, Berthele A, Kümpfel T, Linker RA, et al; Neuromyelitis Optica Study Group: Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol 69: 239-245, 2012

20) Cree BA, Lamb S, Morgan K, Chen A, Waubant E, et al: An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64: 1270-1272, 2005

21) Lindsey JW, Meulmester KM, Brod SA, Nelson F, Wolinsky JS: Variable results after rituximab in neuromyelitis optica. J Neurol Sci 317: 103-105, 2012

22) Strand V, Burmester GR, Ogale S, Devenport J, John A, et al: Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumor necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study. Rheumatology 51: 1860-1869, 2012

23) Qian P, Lancia S, Alvarez E, Klawiter EC, Cross AH: Association of neuromyelitis optica with severe and intractable pain. Arch Neurol 69: 1482-1487, 2012

24) Vallejo R, Tilley DM, Vogel L, Benyamin R: The role of glial and the immune system in the development and maintenance of neuropathic pain. Pain Pract 10: 167-184, 2010

25) Arruda JL, Sweitzer S, Rutkowski MD, DeLeo JA: Intrathecal anti-IL-6 antibody and IgG attenuates peripheral nerve injury-induced mechanical allodynia in the rat: possible immune modulation in neuropathic pain. Brain Res 879: 216-225, 2000

26) Ayzeberg I, Kleiter I, Schroder A, Hellwig K, Chan A, et al: Interleukin-6 receptor blockade in neuromyelitis optica patients non-responsive to anti-CD20 therapy. JAMA Neurol 70: 394-397, 2013

27) Kieseier BC, Stuve O, Dehmel T, Goebels N, Leussink VL, Mausberg AK, et al: Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica. JAMA Neurol 70: 390-393, 2013